Literature DB >> 27667490

[Autoimmune Encephalitis Associated with Malignant Tumors].

Takashi Inuzuka1.   

Abstract

Autoimmune encephalitis consists of limbic symptoms and signs associated with antibodies against neuronal cell-surface antigens or intracellular antigens. Some cases are known to be associated with anti-channel or anti-receptor-related molecule antibodies. Whether these cases are paraneoplastic depends on the kinds of antigens that the antibodies are produced against. Other cases due to well-characterized onco-neural antibodies are almost always paraneoplastic and are generally resistant to anti-tumor therapy and/or immunotherapy. An exception is anti-Ma2 antibody-positive encephalitis associated with a testicular tumor. Antibodies for intracellular antigens are considered not to be pathogenic. Rather, the T-cell response is thought to be responsible. These antibodies are useful markers for the diagnosis of paraneoplastic disorders and in the search for underlying cancer, as neurological symptoms often precede tumor diagnosis. There is a relationship among onco-neural antibodies, clinical features, tumor types, and response to immunotherapy. Here we describe the characteristics of autoimmune encephalitis cases with antibodies against different intracellular antigens, such as Hu, Ma2, CRMP5, or amphiphysin.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27667490     DOI: 10.11477/mf.1416200551

Source DB:  PubMed          Journal:  Brain Nerve        ISSN: 1881-6096


  2 in total

1.  Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF-κB/COX-2 signaling pathways.

Authors:  Jun Zhao; Jiabin Zhu; Xiaoshu Lv; Jinshan Xing; Shuang Liu; Chen Chen; Yinghui Xu
Journal:  Onco Targets Ther       Date:  2017-11-15       Impact factor: 4.147

2.  Isoalantolactone inhibits IKKβ kinase activity to interrupt the NF-κB/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma.

Authors:  Jin-Shan Xing; Xun Wang; Yu-Long Lan; Jia-Cheng Lou; Binbin Ma; Tingzhun Zhu; Hongqiang Zhang; Dongsheng Wang; Zhikuan Yu; Zhongbo Yuan; Xin-Yu Li; Bo Zhang
Journal:  Cancer Med       Date:  2019-02-10       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.